InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa

  • Phase III study to include a new primary endpoint, the modified HiSCR
  • New primary endpoint and Phase III trial design to be discussed in detail at virtual R&D event on February 3rd
  • Phase III program to focus on HS patients with active draining tunnels and will start enrolling patients in Q2

JENA, Germany I January 05, 2022 I InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the initiation of the Phase III program with vilobelimab in hidradenitis suppurativa (HS) patients with active draining tunnels. The new primary endpoint, called modified HiSCR (Hidradenitis Suppurativa Clinical Response), as suggested by the FDA, will include measuring the reduction of all three types of lesions – inflammatory nodules, abscesses and draining tunnels.

“We are excited to be able to move into pivotal testing with vilobelimab for the treatment of hidradenitis suppurativa, a debilitating and painful disease with limited treatment options,” said Dr. Korinna Pilz, Chief Clinical Development Officer. “We have incorporated the FDA’s feedback into the trial design and can now move forward with initiating the Phase III trial. We expect to begin patient recruitment in the second quarter of this year.”

InflaRx completed a Type A meeting with the U.S. Food & Drug Administration (FDA) in September 2021 to align on the Phase III HS study design. The FDA response was supportive of a pivotal study program that focuses on patients with active draining tunnels and a new primary efficacy endpoint that includes measuring the reduction of all three lesions – inflammatory nodules, abscesses and draining tunnels. InflaRx incorporated the FDA’s input and submitted the Phase III protocol to the Agency in late November 2021. The FDA had no comments during the 30-day review period; so, InflaRx will now begin the study, including bringing on clinical sites. Enrollment is slated to start in Q2 2022.

Virtual R&D event to highlight vilobelimab in HS, including Phase III study design
InflaRx will host a virtual R&D event on Thursday, February 3rd, beginning at 8:30 AM EST/2:30 PM CET. The Company will provide an update on vilobelimab development in HS, including details on the Phase III program. To participate in the conference call, participants may pre-register here and will receive a dedicated link and dial-in details to easily and quickly access the call.

About Vilobelimab (IFX-1):
Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, vilobelimab leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. Vilobelimab has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key “amplifier” of this response in pre-clinical studies. Vilobelimab is believed to be the first monoclonal anti-C5a antibody introduced into clinical development. Over 300 people have been treated with vilobelimab in completed clinical trials, and the antibody has been shown to be well tolerated. Vilobelimab is currently being developed for various indications, including hidradenitis suppurativa, ANCA-associated vasculitis and pyoderma gangraenosum, as well as other areas, including critical COVID-19 and cutaneous squamous cell carcinoma (cSCC).

About InflaRx N.V.:
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary technology to discover and develop first-in-class or best-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit


La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up